Softwr

Healthcare · head to head

Lyra Health vs Paige

Lyra Health logo

Lyra Health

Healthcare

Employer purchased mental health benefit with a curated provider network and measurement based care

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lyra Health covered sessions per member per year are set in the employer contract and vary widely between clients, so employees at two companies both using Lyra can receive very different benefits and the number is never published.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Lyra Health covers Curated provider network, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lyra Health and Paige actually diverge.

Attributes where Lyra Health and Paige differ
AttributeLyra HealthPaige
PlatformsWeb, iOS, AndroidWeb, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lyra Health

  • Curated provider network
  • Measurement based care
  • Self guided digital programmes
  • Coaching tier
  • Dependant and household coverage
  • Higher acuity pathways
  • Employer reporting
  • Global delivery

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Lyra Health

  • An employer whose legacy employee assistance programme has utilisation in the low single digits and cannot demonstrate any clinical outcomenot Paige
  • A company with a distributed workforce needing therapist availability outside major metropolitan areas where the health plan network is thinnot Paige
  • An employer wanting behavioural health outcomes measured with validated instruments so the benefit can be evaluated rather than merely offerednot Paige
  • A multinational standardising mental health support across several countries under one contract and one reporting viewnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Lyra Health
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Lyra Health
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Lyra Health
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Lyra Health

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lyra Health

  • Covered sessions per member per year are set in the employer contract and vary widely between clients, so employees at two companies both using Lyra can receive very different benefits and the number is never published.
  • When a member exhausts the employer funded session allowance, care transitions to the health plan network with its deductibles and copayments, or ends, and this handover is the most common source of employee dissatisfaction with the benefit.
  • The per employee per month fee is charged across the whole eligible population regardless of use, so an employer with low utilisation pays for the entire workforce to serve a small fraction of it.
  • Lyra costs materially more than a traditional employee assistance programme, and the business case depends on utilisation rising enough to justify the difference, which is not guaranteed by the contract.
  • International coverage is real but uneven, and a multinational will find provider depth and language availability in secondary markets well below what is available in the United States, which undermines the single global standard the contract implies.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Lyra Health

On request
  • Lyra Health$undefined/year
    • Per employee per month fee across the eligible population, quoted not published
    • Covered sessions per member per year negotiated separately and varying widely by client
    • Dependant and household eligibility affects the rate

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Lyra Health if

  • You need curated provider network.
  • You work on Web, iOS, Android.
  • You also want measurement based care.
Lyra Health review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Lyra Health or Paige better?
Neither clearly leads. Lyra Health starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lyra Health or Paige?
Lyra Health starts at On request and Paige at On request.
Does Lyra Health or Paige run on more platforms?
Lyra Health runs on Web, iOS, Android. Paige runs on Web, Cloud, On-premise.
What is Lyra Health best used for?
Lyra Health is most often used for an employer whose legacy employee assistance programme has utilisation in the low single digits and cannot demonstrate any clinical outcome, a company with a distributed workforce needing therapist availability outside major metropolitan areas where the health plan network is thin, an employer wanting behavioural health outcomes measured with validated instruments so the benefit can be evaluated rather than merely offered, a multinational standardising mental health support across several countries under one contract and one reporting view. Of those, an employer whose legacy employee assistance programme has utilisation in the low single digits and cannot demonstrate any clinical outcome and a company with a distributed workforce needing therapist availability outside major metropolitan areas where the health plan network is thin are not what Paige is typically brought in for.
What can Lyra Health do that Paige cannot?
Lyra Health covers Curated provider network, Measurement based care, Self guided digital programmes, Coaching tier. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Lyra Health: How is Lyra priced?

Per employee per month across the eligible population, billed to the employer. The rate is quoted, never published, and depends on headcount, dependant eligibility and the contracted session allowance.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Lyra Health: How many therapy sessions do employees get?

It depends entirely on what the employer bought. Session allowances vary widely between clients, so ask your benefits team for the contracted number rather than assuming a standard.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Lyra Health: Who pays, the employer or the health plan?

The employer pays the per employee per month fee and funds the covered sessions. After the allowance is exhausted, cost typically shifts to the health plan and the member.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Lyra Health: Is there a minimum headcount?

Lyra does not publish one, but it sells primarily to mid sized and large employers and the commercial model does not suit small companies.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Lyra Health

More on Paige

Keep looking

Other head to heads